Breakthrough in the fight against esophageal cancer: Bielefeld study convinced!
Breakthrough in the fight against esophageal cancer: Bielefeld study convinced!
worldwide, around 85,700 people develop adenocarcinoma of the esophagus, a form of esophageal cancer, which mainly develops in the lower section of the esophagus. This cancer has increased drastically in the past 30 years, whereby the frequency has sifted. The main cause of the development of adenocarcinoma is the ascent of gastric acid, which can lead to cell changes. Risk factors include obesity, smoking, alcohol consumption and a high -fat diet. Men who are diagnosed three times more often than women and three years earlier three years earlier are particularly affected.
A current study published in the renowned New England Journal of Medicine now brings new findings to the treatment of this disease. Professor Dr. Jens Höppner, head of the university clinic for general and visceral surgery at the Lippe Clinic, carried out the ESOPEC study with an interdisciplinary team. 25 facilities specialized in cancer in Germany were involved in this multicenter, prospective and randomized study. The aim was to compare the effectiveness of two different treatment methods: chemotherapy and radiation therapy after the cross protocol and perioperative chemotherapy as part of the flot protocol.
results of the study
A total of 438 patients took part in the ESOPEC study between 2016 and 2020. By the end of 2023, it was followed how many of them suffered a relapse or died of the disease. The results show that patients who received chemotherapy perioperatively lived an average of 66 months, which is a significant improvement of 29 months compared to those who were only treated before the operation. This data corresponds to around 30 percent lower risk of death for the group that received perioperative chemotherapy. The primary endpoint of the study was the overall survival with a minimum observation period of 36 months, with secondary goals such as progression -free survival and quality of life being examined.
A remarkable aspect of the study is that it was not financed by a pharmaceutical company, which contributes to the credibility of the results. The newly gained knowledge already has an impact on national and international treatment guidelines, so that the European ESOM guidelines were adapted after the publication of the study results.
cancer and survival prospects
The urgency of measures to combat esophageal cancer is also underlined by the current statistics. According to data, 1,782 women and 5,736 men in Germany have been affected by esophageal cancer, whereby the death rate in men is estimated at 6.6 per 100,000 per 100,000 in women. The 5-year survival rate is only 25 percent for men and 24 percent for women, which illustrates the unfavorable survival prospects of this diagnosis.
The ESOPEC study could now play a crucial role in improving these figures. Through targeted treatments, the chances of survival for patients with localized esophageal adenocarcinoma could be significantly increased. As already reported by current.uni-bielefeld.de , the effects of the study have also been very well received on international specialist congresses. High-ranking presentations, including at the ASCO annual conference, have illustrated the relevance and influence of research.
The data and knowledge from the ESOPEC study could not only revolutionize the treatment methods for esophageal cancer, but also have a positive impact on the future of many affected patients.
Details | |
---|---|
Ort | Bielefeld, Deutschland |
Quellen |
Kommentare (0)